Covidien licenses apoptosis imaging technology
Diagnostic imaging product developer Covidien Imaging Solutions said that it has signed a license agreement with NewSouth Innovations of Sydney, Australia, to develop a radiolabeled molecular imaging agent for evaluating the efficacy of cancer treatments.

The agent is designed to bind to cancer cells undergoing apoptosis as a result of chemotherapy treatment, according to the St. Louis-based Covidien.

Under terms of the exclusive worldwide agreement, Covidien has product development and commercialization rights for the apoptosis technology, which was invented by Professor Philip Hogg, a co-director of the Lowy Cancer Research Center in Sydney.